Leflunomide in psoriatic arthritis

Autoimmunity Reviews

Volumn 6, Issue 8, 2007, Pages 511-514

  Kaltwasser, Joachim Peter ^a  

^a Zentrum der Inneren Medizin   (Germany)

Author keywords

Clinical trial; Dermatology; Leflunomide; Psoriasis; Psoriatic arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PYRIMIDINE; SALAZOSULFAPYRIDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DACTYLITIS; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENTHESITIS; FINGER JOINT; HUMAN; IMMUNOPATHOLOGY; INTERSTITIAL LUNG DISEASE; LIVER FAILURE; LOADING DRUG DOSE; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MULTICENTER STUDY; PANCYTOPENIA; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; VASCULITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; ISOXAZOLES;

EID: 34548487507     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.12.001     Document Type: Review

References (14)

1. Gladman D.D., Antoni C., Mease P., Clegg D.O., and Nash P. Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis 64 (2005) 14-17
2. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 4 (2003) 441-447
3. Mease P.J., Gladman D.D., and Krueger G.G. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Ann Rheum Dis 64 (2005) 1-2
4. Wong K., Gladman D.D., Husted J., Long J.A., and Farewell V.T. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 40 (1997) 1868-1872
5. Veale D.J., Ritchlin C., and FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64 (2005) 26-29
6. National Psoriasis Foundation. New research shows 1 million U.S. adults suffer from psoriatic arthritis: others may be at risk but not know it. Portland, (OR); NPF Press Release; May 13, 2002 (2002). http://www.psoriasis.org/release%202002.%20psasurvey.htm URL; http://www.psoriasis.org/release 2002. psasurvey.htm
7. Nash P., and Clegg D.O. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 64 (2005) 74-77
8. Kaltwasser J.P., and Behrens F. Leflunomide: long-term clinical experience and new uses. Expert Opin Pharmacother 6 (2005) 787-801
9. Kaltwasser J.P., Nash P., Gladman D., Rose Ch.F., Behrens F., Jones P., et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 50 (2004) 1939-1950
10. Breedveld F.C., and Dayer J.M. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59 (2000) 841-849
11. Liang G.C., and Barr W.G. Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol 7 6 (2001) 366-370
12. Reich K., Hummel K.M., Beckman I., Mossner R., and Neumann C. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol 146 (2002) 335-336
13. Nash P., Thaci D., Behrens F., and Kaltwasser J.P. Leflunomide improves psoriasis in patients with psoriasis arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212 (2006) 238-249
14. Cannon G.W., Strand V., Scarazzini L., and Holden W.L. Comparison of adverse event reporting rates for etanercept, infliximab, leflunomide and methotrexate between September 1998 and June 2003 (Abstract). Arthritis Rheum 50 9 Suppl (2004) 561 Abs: 1469, 68th Ann.Sci Meeting Amer. Coll. Rheumatology, San Antonio (Oct. 2004)